Improving therapy acceptance and quality of life of patients with endometriosis through a web-based application for the management of therapy side effects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036232

Enrollment

100

Registered

2025-03-26

Start date

2025-04-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N80

Interventions

Group 1: Endometriosis patients who have been prescribed a hormonal therapy for endometriosis receive unlimited access to a web-based application for smartphone/tablet with information and tips on the

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suspected or confirmed endometriosis, indication for hormone therapy, sufficient knowledge of German

Exclusion criteria

Exclusion criteria: Contraindications to hormone therapy, lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Therapy adherence and satisfaction, determined by validated questionnaires after 3, 6 and 12 months [modified (shortened) EPHect Questionnaire - Standard (EPQ-S) (Vitonis et al., 2014)]	—

Secondary

Measure	Time frame
Pain symptoms, stress caused by side effects of hormone therapy and quality of life, determined by validated questionnaires after 3, 6 and 12 months [modified (shortened) EPHect Questionnaire - Standard (EPQ-S) (Vitonis et al., 2014); Beck Depression Inventory (BDI) (Beck et al., 1961)]	—

Countries

Germany

Contacts

Public ContactSvetlana Tchaikovski

Universitätsklinikum Brandenburg an der Havel, Frauenklinik

svetlana.tchaikovsi@uk-brandenburg.de+49 3381 41 1400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026